MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Hesperidin ameliorates rotenone-induced Parkinson’s disease in mice via improving neuroinflammation and oxidative stress

    D. Singh (Prayagraj, India)

    Objective: The goal of the present study is to examine the neuroprotective property of hesperidin on rotenone-induced Parkinson's disease in mice. Background: The second most…
  • 2023 International Congress

    Treatment induced psychogenic movement disorders: a case series

    V. Palakuzhy, S. Anderson, N. Patel (Chicago, USA)

    Objective: To describe new onset psychogenic movement disorders in 2 patients who underwent Deep Brain Stimulation (DBS) for Parkinson’s disease (PD) and MR guided Focused…
  • 2023 International Congress

    NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.

    H. Berven, S. Kverneng, E. Sheard, M. Søgnen, S. Geijerstam, K. Haugarvoll, GO. Skeie, C. Dölle, C. Tzoulis (Bergen, Norway)

    Objective: To determine the safety of oral nicotinamide riboside (NR) 3000 mg daily for 4 weeks in Parkinson’s disease (PD). Secondary objectives: To assess NRs…
  • 2023 International Congress

    Cognitive flexibility associates with atrophy and disrupted connectivity of the cognitive cerebellum in degenerative cerebellar ataxia

    JH. Shin, HJ. Kim, SY. Lee, WT. Yoon, SW. Park, SM. Park, D. Yoo, JY. Lee (Seoul, Republic of Korea)

    Objective: This study was to investigate the features of cognitive flexibility in patients with degenerative cerebellar ataxia, and to identify the pathophysiological correlates of cognitive…
  • 2023 International Congress

    Population-Scale Long-Read Sequencing to Catalog Structural Variants in Parkinson’s Disease

    K. Billingsley (bethesda, USA)

    Objective: We aimed to generate a population scale long-read sequencing dataset to begin to catalog structural variants in Parkinson’s disease (PD) to identify potential new variants…
  • 2023 International Congress

    Fluorescence-lifetime ophthalmoscopy findings in Parkinson’s disease patients with visual disturbances

    K. Shivok, E. Affel, M. Alizadeh, T-W. Liang, D. Kremens, R. Sergott (Philadelphia, USA)

    Objective: We identified fluorescence-lifetime ophthalmoscopy changes in Parkinson’s disease (PD) patients experiencing visual disturbances. Background: Fluorescence-lifetime ophthalmoscopy (FLIO), a novel in vivo imaging method generating…
  • 2023 International Congress

    restless leg syndrome in parkinson’s disease patients: prevalence and correlates with sleep parameters

    S. Diaconu, R. Zosin, L. Irincu, E. Ungureanu, A. Zarnoveanu, V. Vasile, M. Cusnir, N. Enache, C. Falup-Pecurariu (Brasov, Romania)

    Objective: The aim of the present study is to explore the clinical significance and frequency of restless leg syndrome (RLS) in a sample of patients…
  • 2023 International Congress

    The role of structural changes in the retina and the vertical vestibulo-ocular reflex abnormality in gait disorders in Parkinson`s disease

    O. Alenikova, O. Davydova, N. Alenikov (Minsk, Belarus)

    Objective: Our goal was to investigate retinal structural changes as well as changes in visual cortex in PD patients with suppression deficiency of VOR and…
  • 2023 International Congress

    Validation of the EQ-5D-3L in Spinocerebellar Ataxia (SCA)

    M. Buchholz, N. Weber, A. Rädke, J. Faber, T. Schmitz-Hübsch, H. Jacobi, F. Xie, T. Klockgether, B. Michalowsky (Greifswald, Germany)

    Objective: Our study aims to assess the acceptability, validity and responsiveness of the EQ-5D-3L in SCA types 1, 2, 3 and 6. Background: Although health-related…
  • 2023 International Congress

    London-Dhaka Parkinson’s Cognition Study: A collaboration to evaluate cognitive impairment in under-represented Parkinson’s disease patients

    T. Zannat, K. Dey, A. Zirra, A. Haque, E. Camboe, T. Haque, S. Waters, D. Mair, C. Marshall, A. Noyce, A. Habib (Dhaka, Bangladesh)

    Objective: Our aim is to study the prevalence of cognitive impairment (CI) in a diverse group of people with Parkinson's disease (PwP) from East London,…
  • « Previous Page
  • 1
  • …
  • 378
  • 379
  • 380
  • 381
  • 382
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley